The Food and Drug Administration recently approved Norcross, Ga.–based Immucor's PreciseType HEA test to screen blood donations for the sickle cell trait.
The test, first approved in 2015, helps clinicians predict blood compatibility between donors and patients.
Typically, blood banks use solubility testing to screen for the sickle cell trait. Immucor's new molecular approach to identifying the trait aims to increase efficiency and limit the rate of false positives, according to the report.
More articles on supply chain:
Medical device execs call for quicker coverage decisions from CMS
States ranked by 2015 generic drug savings
4 latest FDA approvals